The Oncology Institute, Inc. TOI Clinical trials & other — Total operating revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s clinical trials & other — total operating revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s clinical trials & other — total operating revenue?
- The Oncology Institute, Inc. (TOI) reported clinical trials & other — total operating revenue of $813K in Q1 2026.
- How has The Oncology Institute, Inc.'s clinical trials & other — total operating revenue changed year-over-year?
- The Oncology Institute, Inc.'s clinical trials & other — total operating revenue decreased by 60.2% year-over-year, from $2.05M to $813K.
- What is the long-term trend for The Oncology Institute, Inc.'s clinical trials & other — total operating revenue?
- Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s clinical trials & other — total operating revenue has grown at a -8.0% compound annual growth rate (CAGR), from $6.38M to $4.56M.
- What does clinical trials & other — total operating revenue mean?
- This metric measures the gross inflow of economic benefits generated from the clinical trials and other business segment during the reporting period. It is a primary indicator of the segment's market demand and its contribution to the company's overall top-line performance.